Gerald G Krueger

Summary

Affiliation: University of Utah
Country: USA

Publications

  1. ncbi request reprint Selective targeting of T cell subsets: focus on alefacept - a remittive therapy for psoriasis
    Gerald G Krueger
    Department of Dermatology, University of Utah Health Sciences Center, 50 N Medical Drive, Suite 4B 454, Salt Lake City, UT 84132, USA
    Expert Opin Biol Ther 2:431-41. 2002
  2. ncbi request reprint Current concepts and review of alefacept in the treatment of psoriasis
    Gerald G Krueger
    Department of Dermatology, 4B454 School Medicine, University of Utah Health Sciences Center, 30 N 1900 E, Salt Lake City, UT 84132 2409, USA
    Dermatol Clin 22:407-26, viii. 2004
  3. ncbi request reprint A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis
    Gerald G Krueger
    University of Utah, Salt Lake City, USA
    N Engl J Med 356:580-92. 2007
  4. pmc Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis
    Howa Yeung
    Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 19104, USA
    J Am Acad Dermatol 68:64-72. 2013
  5. doi request reprint Association between IL13 polymorphisms and psoriatic arthritis is modified by smoking
    Kristina Callis Duffin
    Department of Dermatology, University of Utah School of Medicine, 30 North 1900 East, Salt Lake City, Utah 84132, USA
    J Invest Dermatol 129:2777-83. 2009
  6. pmc Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe psoriasis
    Katrina Abuabara
    Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 19104, USA
    J Am Acad Dermatol 68:262-9. 2013
  7. pmc Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting
    Joel M Gelfand
    Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA
    Arch Dermatol 148:487-94. 2012
  8. pmc Genome-wide association analysis identifies three psoriasis susceptibility loci
    Philip E Stuart
    Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan, USA
    Nat Genet 42:1000-4. 2010
  9. doi request reprint A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis
    Gerald G Krueger
    Department of Dermatology, University of Utah School of Medicine, Salt Lake City, UT 84132 2409, USA
    J Dermatolog Treat 19:146-55. 2008
  10. pmc Dermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patients
    Joy Wan
    Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 19104, USA
    J Am Acad Dermatol 66:376-86. 2012

Detail Information

Publications54

  1. ncbi request reprint Selective targeting of T cell subsets: focus on alefacept - a remittive therapy for psoriasis
    Gerald G Krueger
    Department of Dermatology, University of Utah Health Sciences Center, 50 N Medical Drive, Suite 4B 454, Salt Lake City, UT 84132, USA
    Expert Opin Biol Ther 2:431-41. 2002
    ..Alefacept did not alter the primary or acquired immune response in psoriatic patients. Clinical data obtained to date support the use of alefacept as a safe and remittive therapy for psoriasis...
  2. ncbi request reprint Current concepts and review of alefacept in the treatment of psoriasis
    Gerald G Krueger
    Department of Dermatology, 4B454 School Medicine, University of Utah Health Sciences Center, 30 N 1900 E, Salt Lake City, UT 84132 2409, USA
    Dermatol Clin 22:407-26, viii. 2004
    ....
  3. ncbi request reprint A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis
    Gerald G Krueger
    University of Utah, Salt Lake City, USA
    N Engl J Med 356:580-92. 2007
    ..Skin-infiltrating lymphocytes expressing type 1 cytokines have been linked to the pathophysiology of psoriasis. We evaluated the safety and efficacy of a human interleukin-12/23 monoclonal antibody in treating psoriasis...
  4. pmc Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis
    Howa Yeung
    Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 19104, USA
    J Am Acad Dermatol 68:64-72. 2013
    ..Despite widespread dissatisfaction and low treatment persistence in moderate to severe psoriasis, patients' reasons behind treatment discontinuation remain poorly understood...
  5. doi request reprint Association between IL13 polymorphisms and psoriatic arthritis is modified by smoking
    Kristina Callis Duffin
    Department of Dermatology, University of Utah School of Medicine, 30 North 1900 East, Salt Lake City, Utah 84132, USA
    J Invest Dermatol 129:2777-83. 2009
    ..88, P=0.74, CC/non-smoker, prevalence 42% (reference), CC/smoker prevalence 47%, OR 1.21, P=0.47). This study suggests that IL13 polymorphisms associate most strongly with PsA and that smoking may modulate this effect...
  6. pmc Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe psoriasis
    Katrina Abuabara
    Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 19104, USA
    J Am Acad Dermatol 68:262-9. 2013
    ..Physician perceptions can influence prescribing patterns and patient outcomes, and may help to explain variations in clinical practice...
  7. pmc Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting
    Joel M Gelfand
    Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA
    Arch Dermatol 148:487-94. 2012
    ..To compare the effectiveness of biologic systemic therapy, nonbiologic systemic therapy, and phototherapy for treatment of psoriasis...
  8. pmc Genome-wide association analysis identifies three psoriasis susceptibility loci
    Philip E Stuart
    Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan, USA
    Nat Genet 42:1000-4. 2010
    ..We also replicated a recently identified association signal near RNF114 (rs495337, combined P = 2 × 10⁻⁷)...
  9. doi request reprint A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis
    Gerald G Krueger
    Department of Dermatology, University of Utah School of Medicine, Salt Lake City, UT 84132 2409, USA
    J Dermatolog Treat 19:146-55. 2008
    ..To evaluate the safety and efficacy of multiple courses of alefacept in combination with traditional psoriasis therapy for the treatment of chronic plaque psoriasis (CPP)...
  10. pmc Dermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patients
    Joy Wan
    Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 19104, USA
    J Am Acad Dermatol 66:376-86. 2012
    ..Despite increasing therapies for moderate to severe psoriasis, dermatologists' treatment preferences are unknown...
  11. doi request reprint Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort
    Jessica A Walsh
    Division of Rheumatology, University of Utah, Salt Lake City, Utah Electronic address
    J Am Acad Dermatol 69:931-7. 2013
    ..The Psoriasis Area and Severity Index (PASI) is considered the gold standard assessment tool for psoriasis severity, but PASI is limited by its complexity and insensitivity in people with mild psoriasis...
  12. doi request reprint Exploring priority research areas in psoriasis and psoriatic arthritis from dermatologists' perspective: a report from the GRAPPA 2011 annual meeting
    April W Armstrong
    Department of Dermatology, University of California Davis, Sacramento, California 95816, USA
    J Rheumatol 39:2204-10. 2012
    ..Finally, the members supported continued efforts to explore the genetic basis of psoriasis and more studies focused on comparative effectiveness of existing treatments...
  13. ncbi request reprint Alefacept: a novel biologic in the treatment of psoriasis
    Clive M Liu
    Department of Dermatology, University of Utah, 30 North 1900 East 4B454, Salt Lake City, UT 84132, USA
    Drugs Today (Barc) 40:961-74. 2004
    ..This selective effect on the immune system distinguishes alefacept from immunosuppressive therapies that are nonselective...
  14. doi request reprint Obesity in early adulthood as a risk factor for psoriatic arthritis
    Razieh Soltani-Arabshahi
    Department of Dermatology, University of Utah School of Medicine, 30 North 1900 East, Salt Lake City, UT 84132, USA
    Arch Dermatol 146:721-6. 2010
    ..To study whether obesity increases the risk of psoriatic arthritis (PsA), given that obesity is a risk factor for psoriasis and is associated with more severe disease...
  15. doi request reprint Consensus guidelines for the management of plaque psoriasis
    Sylvia Hsu
    Department of Dermatology, Baylor College of Medicine, Houston, TX 77030, USA
    Arch Dermatol 148:95-102. 2012
    ....
  16. doi request reprint Genetic variations associated with psoriasis and psoriatic arthritis found by genome-wide association
    Kristina Callis Duffin
    4A330 School of Medicine, Salt Lake City, UT 84132, USA
    Dermatol Ther 23:101-13. 2010
    ..Many of these genetic variations also associate with immune disorders considered psoriatic co-morbidities, including Crohn's disease and diabetes...
  17. ncbi request reprint Observations of psoriasis in the absence of therapeutic intervention identifies two unappreciated morphologic variants, thin-plaque and thick-plaque psoriasis, and their associated phenotypes
    Tanya E Christensen
    Department of Dermatology, University of Utah School of Medicine, Salt Lake City, Utah 84132 2409, USA
    J Invest Dermatol 126:2397-403. 2006
    ....
  18. ncbi request reprint Development and use of alefacept to treat psoriasis
    Gerald G Krueger
    Department of Dermatology, University of Utah Health Sciences Center, 4B454 School of Medicine, 30 N 1900 E, Salt Lake City, UT 84132 2409, USA
    J Am Acad Dermatol 49:S87-97. 2003
    ..Adverse events in the placebo and active treatment arms did not differ. We conclude that alefacept significantly improves psoriasis and produces durable clinical improvement with a very favorable safety profile...
  19. ncbi request reprint A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis
    Gerald G Krueger
    University of Utah Health Sciences Center, Salt Lake City, USA
    J Am Acad Dermatol 47:821-33. 2002
    ..In previous phase II studies, alefacept significantly improved psoriasis and was well tolerated. The clinical response to alefacept was durable...
  20. pmc National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening
    Alexa B Kimball
    Department of Dermatology, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Am Acad Dermatol 58:1031-42. 2008
    ....
  21. pmc Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways
    Rajan P Nair
    Department of Dermatology, University of Michigan, Ann Arbor, Michigan 48109, USA
    Nat Genet 41:199-204. 2009
    ..Our results expand the catalog of genetic loci implicated in psoriasis susceptibility and suggest priority targets for study in other auto-immune disorders...
  22. ncbi request reprint A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis
    Christopher S Carlin
    Department of Dermatology, University of Utah Health Sciences Center, Salt Lake City, Utah 84132, USA
    J Am Acad Dermatol 50:859-66. 2004
    ..We conclude that PASI 50 equates to a clinically meaningful improvement in psoriasis and represents a discerning primary endpoint...
  23. ncbi request reprint The effect of hair color on the incorporation of codeine into human hair
    Douglas E Rollins
    Department of Pharmacology and Toxicology University of Utah Health Sciences Center, Salt Lake City, Utah 84112, USA
    J Anal Toxicol 27:545-51. 2003
    ..The incorporation of these drugs into hair should be studied carefully in humans to ensure the appropriate interpretation of drug concentrations...
  24. doi request reprint Limitations in screening instruments for psoriatic arthritis: a comparison of instruments in patients with psoriasis
    Jessica A Walsh
    Division of Rheumatology and the Department of Dermatology, University of Utah, Salt Lake City, UT 84109, USA
    J Rheumatol 40:287-93. 2013
    ..To compare the abilities of 3 validated screening instruments to predict the diagnosis of psoriatic arthritis (PsA) in patients with psoriasis...
  25. doi request reprint Psoriatic arthritis is a strong predictor of sleep interference in patients with psoriasis
    Kristina Callis Duffin
    Department of Dermatology, University of Utah, Salt Lake City, Utah 84132, USA
    J Am Acad Dermatol 60:604-8. 2009
    ..We sought to determine what clinical features of psoriasis predict sleep interference...
  26. ncbi request reprint Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial
    Gerald G Krueger
    University of Utah Health Sciences Center, Salt Lake City, Utah 84132 0001, USA
    J Am Acad Dermatol 54:S112-9. 2006
    ..Etanercept provides rapid, significant improvement in psoriatic symptoms and disease...
  27. ncbi request reprint Impact of obesity and smoking on psoriasis presentation and management
    Mark D Herron
    Department of Dermatology, University of Utah School of Medicine, Health Sciences Center, 30 North 1900 East, Salt Lake City, UT 84132, USA
    Arch Dermatol 141:1527-34. 2005
    ..To study the impact of obesity and smoking on psoriasis...
  28. ncbi request reprint A multicenter, randomized, double-blind trial of tazarotene 0.1% cream in the treatment of photodamage
    Sewon Kang
    University of Michigan Medical Center, Department of Dermatology, Ann Arbor, Michigan 48109 0314, USA
    J Am Acad Dermatol 52:268-74. 2005
    ..Previous studies indicate that tazarotene is efficacious in reducing signs of photodamage. Objective We sought to confirm the efficacy and tolerability of tazarotene 0.1% cream in the treatment of facial photodamage...
  29. ncbi request reprint The remittive effects of alefacept
    Gerald G Krueger
    Department of Dermatology, University of Utah Health Sciences Center, Salt Lake City, UT 84132, USA
    J Cutan Med Surg 8:10-3. 2004
    ..Alefacept is a remittive therapy for psoriasis...
  30. ncbi request reprint Ustekinumab: a review in the treatment of plaque psoriasis and psoriatic arthritis
    Daniel Zaghi
    Department of Dermatology, School of Medicine, University of Utah School of Medicine, Salt Lake City, UT 84132, USA
    J Drugs Dermatol 11:160-7. 2012
    ..This is a concise and current review of ustekinumab in the treatment of plaque psoriasis and psoriatic arthritis, with focus on data from the seven published clinical trials...
  31. ncbi request reprint Pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adult and pediatric patients with moderate to severe atopic dermatitis
    Gerald G Krueger
    University of Utah Health Sciences Center, Salt Lake City, UT 84132, USA
    J Drugs Dermatol 6:185-93. 2007
    ..To characterize the pharmacokinetics of tacrolimus after topical application in adult and pediatric patients with moderate to severe atopic dermatitis from all clinical trials in which tacrolimus blood levels were obtained...
  32. doi request reprint Summary of minutes of the GRAPPA meeting adjacent to the American Academy of Dermatology 67th Annual Meeting
    Wolf Henning Boehncke
    Department of Dermatology, Boston Medical Center, Boston University School of Medicine, Boston, MA 02118, USA
    J Rheumatol 38:553-6. 2011
    ..Key results and minutes of the San Francisco meeting were presented at the 2009 GRAPPA annual meeting in Stockholm, Sweden, and are summarized here...
  33. ncbi request reprint From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis
    Mark Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, New York, New York, USA
    J Am Acad Dermatol 58:94-105. 2008
    ..Biologics are widely used in the treatment of psoriasis and psoriatic arthritis...
  34. doi request reprint A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach
    Bruce Strober
    Department of Dermatology, New York University Medical Center, New York, NY, USA
    J Am Acad Dermatol 61:S1-S46. 2009
    ..The final rankings and analysis provide guidance for practical, safe, and efficacious treatment options in a number of complex psoriasis scenarios...
  35. doi request reprint Genetic variations in cytokines and cytokine receptors associated with psoriasis found by genome-wide association
    Kristina Callis Duffin
    Department of Dermatology, School of Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah 84132 2409, USA
    J Invest Dermatol 129:827-33. 2009
    ..These discoveries pose the challenge of elucidating the role of common genetic variants in susceptibility to and manifestations of psoriasis...
  36. ncbi request reprint Seborrheic keratoses: a study comparing the standard cryosurgery with topical calcipotriene, topical tazarotene, and topical imiquimod
    Mark D Herron
    University of Utah, Department of Dermatology, School of Medicine, Salt Lake City, UT, USA
    Int J Dermatol 43:300-2. 2004
    ..Patients with seborrheic keratoses frequently desire an effective topical therapy for seborrheic keratoses...
  37. ncbi request reprint Efficacy of acitretin and commercial tanning bed therapy for psoriasis
    Christopher S Carlin
    Department of Dermatology, University of Utah Health Sciences Center, Salt Lake City, 84132, USA
    Arch Dermatol 139:436-42. 2003
    ..To assess the efficacy of acitretin and commercial tanning bed therapy for the treatment of moderate to severe chronic plaque-type psoriasis...
  38. pmc Genetics of psoriasis and psoriatic arthritis: update and future direction
    Kristina Callis Duffin
    Department of Dermatology, University of Utah, Salt Lake City, Utah, USA
    J Rheumatol 35:1449-53. 2008
    ..This article is a summary of that presentation and a review of the literature...
  39. pmc Multiple Loci within the major histocompatibility complex confer risk of psoriasis
    Bing Jian Feng
    Department of Dermatology, University of Utah School of Medicine, Salt Lake City, UT, USA
    PLoS Genet 5:e1000606. 2009
    ..These results demonstrate that there are at least two additional loci within the MHC conferring risk of psoriasis...
  40. ncbi request reprint Induction of dramatic hyperpigmentation in a patient with generalized lichen planus treated with re-PUVA
    Christopher S Carlin
    Department of Dermatology, University of Utah, 50 North Medical Drive, Salt Lake City, UT 84132, USA
    J Cutan Med Surg 6:125-7. 2002
    ..Retinoids plus PUVA (re-PUVA) may be used in the treatment of lichen planus in cases that do not respond to monotherapy. Hyperpigmentation is a potential side effect of re-PUVA therapy...
  41. doi request reprint Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
    Kim A Papp
    Probity Medical Research, Waterloo and University of Western Ontario, London, ON, Canada
    Lancet 371:1675-84. 2008
    ..This study assessed the efficacy and safety of ustekinumab in psoriasis patients and assessed dosing intensification in partial responders...
  42. ncbi request reprint Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis
    Arthur Kavanaugh
    Division of Rheumatology, Allergy and Immunology, University of California at San Diego, 9500 Gilman Drive, San Diego, CA 92093, USA
    J Rheumatol 33:2254-9. 2006
    ..To examine the effect of infliximab on employment status, time lost from work, and productivity in a double-blind, placebo-controlled study of patients with active psoriatic arthritis (PsA)...
  43. ncbi request reprint A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis
    Mark Lebwohl
    Departments of Dermatology, Mount Sinai Medical Center, New York, NY 10029 6574, USA
    Int J Dermatol 41:269-74. 2002
    ..A clobetasol propionate foam product is as effective as clobetasol propionate solution in the treatment of scalp psoriasis...
  44. ncbi request reprint Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial
    Steven R Feldman
    Wake Forest University School of Medicine, Winston Salem, North Carolina 27157 1071, USA
    J Am Acad Dermatol 53:887-9. 2005
    ..At week 12, improvement in Dermatology Life Quality Index was 47% to 61% with etanercept compared with 11% with placebo (P < .0001). Etanercept rapidly and substantially improved patients' health-related quality of life...
  45. ncbi request reprint An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy
    Bernard Goffe
    Dermatolog Associates, Seattle, Washington 98101, USA
    Clin Ther 27:1912-21. 2005
    ..Information on longer-term safety and tolerability is needed to confidently prescribe alefacept therapy for chronic plaque psoriasis beyond 1 or 2 courses...
  46. ncbi request reprint Psoriasis options abound. Ongoing research on Enbrel and Raptiva supports their use in psoriasis treatment
    Gerald G Krueger
    Health News 10:10-1. 2004
  47. ncbi request reprint A randomized trial of etanercept as monotherapy for psoriasis
    Alice B Gottlieb
    Clinical Research Center, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, 08901 0019, USA
    Arch Dermatol 139:1627-32; discussion 1632. 2003
    ..To determine safety and efficacy of monotherapy with etanercept...
  48. ncbi request reprint Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks
    Gerald D Weinstein
    University of California, Irvine, USA
    J Am Acad Dermatol 48:760-7. 2003
    ..Tazarotene in a gel formulation is widely used in the treatment of psoriasis...
  49. ncbi request reprint Keratoderma blennorrhagicum
    Scott R Florell
    N Engl J Med 349:2367-8. 2003
  50. ncbi request reprint AAD consensus statement on psoriasis therapies
    Jeffrey P Callen
    J Am Acad Dermatol 49:897-9. 2003
  51. pmc A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes
    Michele Cargill
    Celera, Alameda, CA 94502, USA
    Am J Hum Genet 80:273-90. 2007
    ..These data, and the previous observation that administration of an antibody specific for the IL-12p40 subunit to patients with psoriasis is highly efficacious, suggest that these genes play a fundamental role in psoriasis pathogenesis...
  52. ncbi request reprint Consensus on a core set of domains for psoriatic arthritis
    Dafna D Gladman
    J Rheumatol 34:1167-70. 2007
    ..quot;..
  53. ncbi request reprint An analysis of select pathogenic messages in lesional and non-lesional psoriatic skin using non-invasive tape harvesting
    Nicholas R Benson
    DermTech International, La Jolla, California 92037, USA
    J Invest Dermatol 126:2234-41. 2006
    ..Data demonstrate that tape stripping reveals mRNA markers not detected in biopsy samples and thus the method may be a useful supplement to biopsy...
  54. pmc The 5q31 variants associated with psoriasis and Crohn's disease are distinct
    Yonghong Li
    Celera, 1401 Harbor Bay Parkway, Alameda, CA 94502, USA
    Hum Mol Genet 17:2978-85. 2008
    ..These results identify the most significant 5q31 risk variants for psoriasis and suggest that distinct 5q31 variants contribute to CD and psoriasis risk...